As per market sources, the stock is trading at a modest GMP (grey market premium) of Rs 2, implying a listing upside of just about 1% over the issue price. While muted, this suggests that the listing may remain steady rather than see a dramatic pop.
The IPO comprised a fresh issue of Rs 64.48 crore and an offer for sale worth Rs 15.60 crore.
Incorporated in 2015, Chemkart India operates as a distributor of food and health ingredients, bridging global suppliers with Indian businesses in the B2B nutrition and supplement space.
Its product basket includes amino acids, vitamins, proteins, herbal extracts, sports nutrition ingredients, and nucleotides. These products are widely used in dietary supplements, functional foods, and health drinks.
The company operates a 28,000+ sq. ft. warehousing and processing facility in Bhiwandi, with capabilities for grinding, blending, sealing, and labeling. It also plans to expand operations by investing in its wholly-owned subsidiary Easy Raw Materials Pvt Ltd using the IPO proceeds.Financially, Chemkart posted a 67% jump in PAT in FY25. It reported an EBITDA of Rs 32.76 crore and healthy margins of 16.12%.The stock’s near-flat GMP signals cautious optimism ahead of listing. Investors may await the actual debut to see if anchor interest and robust financials can sustain upward momentum in a market that’s becoming increasingly selective.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
